our capabilities
Uniquely integrated formulation, device and development capabilities
We effectively integrate all technologies and disciplines required to deliver an inhaled product.
Investors
Share price
Latest results
- 26 Mar 2018 | Investor centrePreliminary results for the year ended 31 December 2018
- 11 Sep 2018 | Financial reportsInterim for the six months ended 30 June 2018
Vectura news
Jul 16, 2019, 11:07 AM
Jun 10, 2019, 8:30 AM
May 24, 2019, 9:27 AM
May 15, 2019, 12:08 PM
Investment case
1
Differentiated inhalation development capabilities
2
In-market product cash flow generation
3
Focused R&D strategy with pipeline progression and partnering potential
4
Focus on Operational Excellence
5
Strong cash flow generation and capital discipline